Business context and reporting period
Registrant: AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), not Talphera, Inc. as specified in the request metadata. This unaudited Form 10-Q covers the quarter ended March 31, 2019; comparative results are for Q1 2018.
AcelRx develops and commercializes therapies for acute pain in medically supervised settings. The U.S. launch of FDA-approved DSUVIA began in Q1 2019. DZUVEO is approved in Europe, but AcelRx had not secured a European commercialization partner. Zalviso is marketed in Europe by Grünenthal; its U.S. NDA had not been resubmitted, and resubmission timing remained under evaluation.
Key financial metrics
Amounts below are in millions of dollars except per-share data.
| Metric | Q1 2019 | Q1 2018 / comparison |
|---|---|---|
| Total revenue | $0.265 | $0.343 |
| Net product sales | $0.047 | $0 |
| Operating expenses | $12.583 | $8.612 |
| Operating loss | $(12.318) | $(8.269) |
| Net loss | $(13.674) | $(11.592) |
| Net loss per share, basic and diluted | $(0.17) | $(0.23) |
| Operating cash used | $(13.240) | $(7.374) |
Aggregate cost of goods sold was $1.230 million, exceeding total revenue; the filing does not present a product-specific gross margin. At March 31, cash and cash equivalents were $73.312 million and short-term investments were $16.838 million, or $90.150 million combined (versus $105.715 million at December 31, 2018). Cash, cash equivalents and restricted cash were $73.490 million.
Total assets were $113.444 million and total liabilities $121.335 million, producing a stockholders’ deficit of $7.891 million. Hercules debt was $10.026 million, classified as current, and scheduled to mature March 1, 2020. The separate liability associated with monetized future royalties was $95.218 million. Operating lease liabilities totaled $5.158 million.
Material changes versus Q1 2018
- Revenue declined $0.078 million. Q1 2019 included $0.047 million of initial DSUVIA sales; collaboration revenue fell to $0.218 million from $0.274 million, principally as Grünenthal reduced existing Zalviso inventory. DoD contract revenue was nil versus $0.069 million; the contract period ended February 28, 2019.
- Operating expenses rose $3.971 million and net loss widened $2.082 million. SG&A increased $5.991 million, or 150%, to support DSUVIA commercialization, while R&D decreased $2.136 million, or 61%, as development programs neared completion and personnel shifted toward commercialization.
- Operating cash use increased $5.866 million. Cash and investments declined $15.565 million from year-end, primarily to fund operations and launch activity.
- Interest expense on Hercules debt declined to $0.376 million from $0.643 million, while non-cash interest on the royalty-sale liability was $1.607 million versus $2.816 million. The royalty liability’s estimated prospective effective rate was revised to approximately 7% because projected European Zalviso royalties were lower than originally expected.
Outlook, commentary and risks
- Management expected existing capital resources to fund operations through at least the end of Q2 2020, based on current plans. It warned that resources likely would not fund operations until revenues become sufficient; additional financing may be required and may be unavailable or dilutive.
- Management expected 2019 SG&A to rise versus 2018 due to DSUVIA commercialization and anticipated approximately $7 million of non-cash interest expense on the royalty-sale liability during 2019.
- AcelRx planned to install an automated DSUVIA packaging line during 2019, with qualified product expected from the line beginning in 2020; management anticipated lower cost of goods sold from 2020 onward. Execution, qualification and regulatory approval were not assured.
- DSUVIA sales were at an early stage, and the product is restricted by a REMS to certified, supervised healthcare settings. Key risks include market and payer acceptance, opioid-related regulatory and reputational scrutiny, safety monitoring, and competition.
- For Zalviso, the FDA may require further work or may disagree with the company’s interpretation of device-error and inadvertent-dispensing data, delaying or preventing U.S. approval. European sales and royalties had been limited; most royalty rights and certain milestones were sold to PDL, and royalty revenue for 2019 was expected to be minimal.
- Other significant risks include reliance on limited or single-source suppliers and contract manufacturers, potential manufacturing cost pressure on Zalviso, need for a DZUVEO partner, and dependence on future capital. DSUVIA also has a deferred pediatric postmarketing study requirement; the protocol was due by August 2020.
- The company reported no material legal proceedings and stated disclosure controls were effective at the reasonable-assurance level, with no material quarterly change in internal control over financial reporting.
Important facts for investors to verify
- Confirm the registrant identity: the supplied filing is AcelRx Pharmaceuticals, Inc., not Talphera, Inc.
- Track DSUVIA adoption, net sales, certified-site and formulary access, and whether commercial growth improves the substantial operating cash burn.
- Monitor cash runway against the Q2 2020 estimate, financing needs, and the planned increase of up to $40 million in Cantor ATM capacity (prospectus supplement covering up to $46.564 million, including prior remaining capacity).
- Check timing and FDA feedback on any Zalviso NDA resubmission, including treatment of dropped tablets and possible label or REMS restrictions.
- Assess automated packaging-line qualification and product supply continuity, as well as Grünenthal inventory/orders and any DZUVEO partnership progress.
- Review Hercules repayment requirements and the growing royalty-monetization liability, including changes in projected royalties and effective interest assumptions.